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Background: The potential use of nucleic acids as therapeutic drugs have triggered the quest for 
oligonucleotide conjugates with enhanced cellular permeability. To this end, the biophysical aspects of 
previously reported potential lipid oligodeoxynucleotide conjugates were studied including its membrane-
binding properties and cellular uptake.  
Methods: These conjugates were fully characterized by MALDI-TOF mass spectrometry and HPLC 
chromatography. Their ability to insert into lipid model membrane systems was evaluated by Langmuir 
balance and confocal microscopy followed by the study of the internalization of a lipid 
oligodeoxynucleotide conjugate bearing a double-tail lipid modification (C28) into different cell lines by 
confocal microscopy and flow cytometry. This compound was also compared with other lipid containing 
conjugates and with the classical lipoplex formulation using Transfectin as transfection reagent. 
Results: This double-tail lipid modification showed better incorporation into both lipid model membranes 
and cell systems. Indeed, this lipid conjugation was capable of inserting the oligodeoxynucleotide into 
both liquid-disordered and liquid-ordered domains of model lipid bilayer systems and produced an 
enhancement of oligodeoxynucleotide uptake in cells, even better than the effect caused by lipoplexes. In 
addition, in β2 integrin (CR3) expressing cells this receptor was directly involved in the enhanced 
internalization of this compound. 
Conclusions: All these features confirm that the dual lipid modification (C28) is an excellent modification 
for enhancing nucleic acids delivery without altering their binding properties. 
General significance: Compared to the commercial lipoplex approach, oligodeoxynucleotide conjugation 
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LOC, lipid oligonucleotide conjugate; TLC, thin-layer chromatography; ACN, acetonitrile; TEAA, 
triethylammonium acetate; TOF, time-of-flight; ODN, oligodeoxynucleotide; CPG, controlled-pore glass; 
PBS, phosphate-buffered saline; DOPC, 1,2-dioleyl-L-α-phosphatidylcholine; GUV, giant unilamellar 
vesicle; SPB, supported planar bilayer; eSM, egg sphingomyelin; Chol, cholesterol; Ld, liquid-disordered; 
Lo, liquid-ordered; MLV, multilamellar vesicle; SUV, small unilamellar vesicle; AFM, atomic force 
microscopy; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; GMFI, Geometric 
Mean Fluorescence Intensity; PFA, paraformaldehyde 
 
1. Introduction 
The ability of some small nucleic acid-based molecules such as DNA decoys, triple helix forming 
oligonucleotides, RNA decoys, antisense oligonucleotides, ribozymes, DNAzymes, siRNAs or aptamers 
to silence specific genes or to inhibit the biological activity of specific proteins has generated great 
interest for their use as research tools and therapeutic agents [1-3]. Unfortunately, biological applications 
of oligonucleotides meet a huge limitation namely cellular accessibility [4]. In fact, phospholipid bilayers 
represent a strong barrier for the highly negatively charged phosphodiester backbone of the 
oligonucleotides, leading to an extremely poor penetration across the cell membrane. Nevertheless, 
simple elimination of the anionic charge does not improve cellular uptake, as evidenced by chemically 
modified neutral backbone-containing oligonucleotides [5]. Therefore developing an appropriate delivery 
system in order to achieve their efficient cellular uptake remains an important challenge. In this regard, 
the use of lipid-based systems has long been considered as a possible method to solve cell permeation 
problems [6]. 
The introduction of both neutral and cationic lipids into oligonucleotides is one of the approaches to 
improve the delivery of these kinds of biomolecules, thereby favoring interaction with, or insertion into the 
plasma membrane along with improving their stability compared to unmodified oligonucleotides [7, 8]. To 
date several lipophilic molecules, including cholesterol, phospholipids, α-tocopherol and alkyl chains, 
have been conjugated to oligonucleotides in order to obtain better clinically acceptable therapeutic drugs 
[9-14]. The main goal of these lipophilic compounds is to improve oligonucleotide delivery and to enhance 
their cellular uptake via receptor-mediated endocytosis by increasing the membrane permeability without 
altering the potential properties of the nucleic acid molecule, thereby achieving the desired gene 
expression inhibition [6, 15-19].  
Recently, our group reported the synthesis of several lipid oligonucleotide conjugates (LOCs) series 
containing neutral and cationic lipids at their 3’- and 5’-termini and their evaluation in vitro in RNA 
interference [20, 21]. We observed that all lipid modifications did not disrupt the RNAi machinery 
obtaining in some cases promising results in inhibiting gene expression without using a transfection 
agent. Indeed, the siRNA carrying the C28 moiety at the 5’-end of the passenger strand showed the best 
inhibitory effects in the absence of the transfecting agent Oligofectamine [21]. It is well-known that cellular 
uptake and the intracellular distribution of nucleic acids may depend on both their surface properties and 
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their interactions with the cell membrane. In the present work, we study such interactions induced by 
LOCs conjugates, specially C28 moiety containing LOC (Fig. 1), using three model membrane systems 
(i.e., monolayers, giant unilamellar vesicles and supported planar bilayers), and several cell lines. As 
shown in Fig. 1, the majority of the lipid modifications at both 3’- and 5’-termini were neutral (Fig. 1, 
compounds 4-7) based on SNALP formulations; except for one of them in which the lipid attached into the 
oligonucleotide at 3’-termini showed a polar group at the end of the lipophilic tail (Fig. 1, compound 3), 
mimicking the effect produced by lipoplex complexes. 
 
2. Materials and methods 
 
2.1. General methods and materials 
All reactions were carried out under argon positive pressure in anhydrous solvents. Commercially 
available reagents and anhydrous solvents were used without further purification. Solvents were distilled 
prior to use and dried using standard methods. Analytical samples were homogeneous as confirmed by 
thin-layer chromatography (TLC) and yielded spectroscopic results were consistent with the assigned 
structures. TLC was performed on silica gel (Alugram Sil G/UV).  
 
2.2. HPLC conditions 
Conditions for semipreparative HPLC: HPLC solutions were Solvent A [5% acetonitrile (ACN) in 100 
mM triethylammonium acetate (TEAA), pH 6.5] and Solvent B (70% ACN in 100 mM TEAA, pH 6.5). 
Column: PRP-1 (Hamilton) 250 x 10 mm. Flow rate 3 ml/min linear gradient from 15 to 100% in B 
(DMTon) and 0 to 85% in B (DMToff) was used with UV detection at 260 nm. Conditions for analytical 
HPLC: HPLC solutions were Solvent A [5% ACN in 100 mM TEAA, pH 6.5] and Solvent B (70% ACN in 
100 mM TEAA, pH 6.5). Column: XBridge OST C18 2.5 µm. Flow rate 1 ml/min linear gradient from 0 to 
85% in B (DMToff) were used with UV detection at 260 nm. Mass spectra were recorded on a MALDI 
Voyager DE RP time-of-flight (TOF) spectrometer (Applied Biosystems, Framingham). Two different 
matrix were used: 2,4,6-trihydroxiacetophenone (10 mg/ml in ACN:H2O 1:1 v/v); ammonium citrate (50 
mg/ml in H2O). 
 
2.3. Synthesis of modified oligonucleotide conjugates with lipids at either 5’- or 3’-termini 
Oligodeoxynucleotides (ODNs) carrying lipids at the 3′-termini were prepared in a DNA synthesizer 
(Applied Biosystems 3400) using standard 2-cyanoethyl phosphoramidites and modified controlled-pore 
glass (CPG) solid supports (Suppl. Scheme S1, compounds CPG-1, CPG-2 and CPG-3). These supports 
were prepared according literature [20, 21].  
ODNs carrying lipids at the 5′-termini were prepared using the same standard 2-cyanoethyl 
phosphoramidites and the appropriate lipid phosphoramidites (Suppl. Schemes S1 and S2, compounds Ι 
and ΙΙ). The syntheses were carried out on CPG supports carrying the 2-(N-[9H-fluoren-9-yl-
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methoxycarbonyl]-4-aminobutyl)propane-1,3-diol linker (Glen Research) to yield oligonucleotide 
conjugates carrying an aliphatic amino group at the 3′-end and the lipid moiety at 5’-termini. In both 
cases, after ammonia deprotection (overnight, 55°C) , the resulting modified oligodeoxynucleotides at both 
3’- (Fig. 1 and Table 1, compounds 3-5) and 5’-termini (Fig. 1 and Table 1, compounds 6-7) were purified 
by HPLC (see conditions below) and conjugates were characterized by mass spectrometry (Table 1). 
Sequence 6 was obtained by using commercially available 3’-amino modifier CPG resin and standard 2-
cyanethyl phosphoramidites purifying it according to conditions described below.  
ODNs carrying lipids at the 3′-termini and an amine group at 5’-termini were prepared using standard 
2-cyanethyl phosphoramidites and modified CPG solid supports (Suppl. Scheme S1, compounds CPG-2 
and CPG-3) as described above. The introduction of the amino group at the 5’-end was achieved using 
the commercially available 5’-amino-modifier-C6-Tfa phosphoramidite (Glen Research) obtaining the 
corresponding LOC conjugates (Table 1, compounds 8 and 9). The amine oligonucleotide conjugates 
were used without further purification in the next step.  
Compounds 1-9 (Table 1) were characterized by MALDI-TOF mass spectrometry and HPLC 
chromatography (Suppl. Figs. S1-S7 and S15-S16). 
 
2.4. Synthesis of modified oligonucleotide conjugates with lipids at either 3’- or 5’-termini carrying 
Alexa 488 as a fluorescent dye 
A solution of the deprotected amine oligonucleotide conjugates described above were passed through 
a column filled with Dowex 50x2, sodium form to remove the interfering ammonium ions coming from the 
cleavage step. Conjugates 6, 7, 8 and 9 (Table 1) were dissolved with 50 µL of an aqueous solution of 0.2 
M NaHCO3 (pH 9). Then, 1.1 equiv of Alexa Fluor 488 tetrafluorophenyl ester dissolved in 30 µL DMF 
was added to the solution and left to react overnight at room temperature. The mixture was concentrated 
to dryness, and the residue was dissolved in H2O (1 ml). The green solutions were purified with Sephadex 
G-25 (NAP-10 Column), and the corresponding oligonucleotide fractions were analyzed and purified by 
semi-preparative HPLC. In the preparation of sequences 12 and 13 (Fig. 1 and Table 1) we were not able 
to separate by HPLC the labeled and unlabelled conjugates (Suppl. Figs. S10 and S11). For this reason 
the mixtures were used in the study. 
Compounds 10-14 (Table 1) were characterized by MALDI-TOF mass spectrometry and HPLC 
chromatography (Suppl. Figs. S8-S11). 
 
2.5. Synthesis of lipid oligonucleotide conjugates carrying Cy5 fluorescent dye at the 5’-end  
In order to obtain the corresponding oligonucleotide conjugates with Cy5 fluorescent label attached at 
5’-termini, we used the same modified CPG solid supports (Suppl. Scheme S1, compounds CPG-1, CPG-
2 and CPG-3). The last coupling was carried out manually, introducing the commercially available Cy5 
phosphoramidite (Glen Research) into the corresponding CPG resins. DNA syntheses were carried out 
using the dmf-dG-CE phosphoramidite (Link Technologies). After deprotection with ammonia solution (6 h 
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at room temperature) and purification by semi-preparative HPLC (see below), the corresponding lipid 
oligonucleotide conjugates with Cy5 were obtained. 
Compounds 15-18 (Table 1) were characterized by MALDI-TOF mass spectrometry and HPLC 
chromatography (Suppl. Figs. S12-S14 and S17). 
All conjugates were lyophilized and dissolved in phosphate-buffered saline (1× PBS) for further 
experiments with lipid membrane model and cell systems. 
 
2.6. Surface tension measurements 
The studies were carried out at 22ºC using a µThrough-S equipment (Kibron Inc., Finland) consisting of 2-
cm rounded multi-well plate that allowed for 1 ml subphase measurements. For possible LOC monolayer 
formation, each LOC was injected into the subphase through an adjusted hole without previous lipid 
spreading, following LOC transition to the interface in terms of changes in surface pressure. For possible 
LOC interaction with lipids, 1,2-dioleyl-L-α-phosphatidylcholine (DOPC) monolayers were formed by 
spreading a small amount of lipid (about 2 nmol) in chloroform:methanol (2:1, v/v) solution over 1× PBS 
solution. After allowing for solvent evaporation, each LOC was added into the subphase and the changes 
in surface pressure were recorded. 
 
2.7. Giant unilamellar vesicle (GUV) preparation 
Sucrose-enclosing GUVs were prepared using the electroformation method as described previously 
[22]. DOPC/egg sphingomyelin (eSM)/cholesterol (Chol) (2:2:1) stock solutions were prepared to contain 
0.4 mol% DiO (3,3′-dioctadecyloxacarbocyanine) or DiD (1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine) (Invitrogen). Both fluorescent probes partition within liquid-disordered 
phases in liquid-disordered-liquid-ordered (Ld-Lo) phase-coexistence-showing bilayers. Vesicles were 
generated in a 300 mM sucrose solution at 60ºC, a temperature rendering bilayers in a fluid phase state. 
30 minutes after electroformation and vesicle equilibration at room temperature, 50 µl vesicles were 
pipetted onto 250 µl of an equiosmolar 1× PBS buffer solution in Lab-Tek Chamber slides (Thermo Fisher 
Scientific, NY, USA).  
 
2.8. Supported planar bilayer (SPB) preparation 
Planar bilayer preparation on mica substrate was performed using the vesicle adsorption technique 
[23]. Briefly, DOPC/eSM/Chol (2:2:1) multilamellar vesicles (MLVs) were initially prepared by mixing the 
appropriate amount of synthetic pure lipids dissolved in chloroform/methanol (2:1, v/v). As in GUVs 
preparation, 0.4% of the lipophilic fluorescent probes DiO or DiD in chloroform/methanol (2:1) were also 
pipetted into the lipid mixture in order to visualize the Ld phase of these bilayer systems. Small unilamellar 
vesicles (SUVs) were then obtained after sonication of the MLV suspension at 60°C for 1 h in a FB-1504 9 
bath sonicator (Fisher Scientific, Waltham, MA). 60 µl SUVs was added to a 1.2-cm2 freshly cleaved mica 
substrate previously mounted onto a BioCell coverslip-based liquid cell for atomic force microscopy (AFM) 
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measurements (JPK Instruments, Berlin, Germany) and hydrated with 120 µl 1× PBS, containing 10 mM 
CaCl2 at 60°C. Final lipid concentration was 150 µM. Ves icles were left to adsorb for 30 min at 55°C. 
Non-adsorbed vesicles were then discarded by washing the samples 10 times with assay buffer at 60°C 
in the absence of CaCl2. Finally, 400 µl PBS was added to the SPBs at 60°C  and left to equilibrate at 
room temperature for 45 min before confocal microscopy image acquisition. 
 
2.9. Experiments of LOC incorporation into GUVs and SPBs by confocal microscopy 
Images were obtained in an inverted fluorescence confocal microscope (Leica TCSSP5, Leica 
Microsystems, Wetzlar, Germany). Briefly, 8 well-Lab-Tek Chamber slides pre-treated with bovine serum 
albumin (to avoid vesicle rupture) where GUVs were sedimented at the bottom of each well containing 1× 
PBS due to the higher density of the enclosed sucrose, or biocell-liquid-cell containing SPBs were placed 
on top of the microscope followed by image acquisition with a 40× LD objective using an excitation 
wavelength of 488 and 633 nm for DiO and DiD, respectively, and the emission was retrieved between 
505-540 nm for DiO and 655-795 nm for DiD. Binding of Alexa 488-labelled and Cy5-labelled LOCs to 
fluorescently labelled GUVs or SPBs was observed under the microscope in sequential mode imaging, 
using the same excitation and emission wavelengths for Alexa 488 and Cy5 as for DiO and DiD, 
respectively. Image treatment was performed using Leica Application Suite software. 
 
2.10. Cell Lines 
HeLa (cervical carcinoma) cell line was kindly provided by Prof. Alfredo Berzal (Instituto de 
Parasitología y Biomedicina “López-Neyra”, CSIC, Granada, Spain). PANC-1, C2C12 and RAW 264.7 
cell lines were generously donated by Prof. Antonio Gómez-Muñoz (Departamento de Bioquímica y 
Biología Molecular, EHU/UPV, Leioa, Spain). CHO K1, CHO CR3+, J774A.1 and J774A.1 CR3- cell lines 
were kindly provided by Prof. Cesar Martín (Unidad de Biofísica, Centro Mixto CSIC-UPV/EHU and 
Departamento de Bioquímica y Biología Molecular, EHU/UPV, Leioa, Spain).  
HeLa cell line is the most commonly used human cell line in scientific research. In this study 
U87.CD4.CXCR4 a human glioblastoma-astrocytoma cell line which expresses CD4 receptor and CXCR4 
co-receptor in the cell surface was used. It has epithelial morphology and it is usually used as an in vitro 
model of human glioblastoma cells to investigate the cytotoxic effect of chemotherapeutic drugs towards 
cancer cells. PANC-1 cell line is a human pancreatic carcinoma, epithelial-like cell line that is commonly 
used as an in vitro model of non-endocrine pancreatic cancer for tumorigenicity studies. C2C12 cell line is 
a subclone of mouse myoblast that differentiates rapidly, forming contractile myotubes and producing 
characteristic muscle proteins. RAW 264.7 cell line is a monocyte/macrophage cell line obtained from 
Abelson murine leukemia virus-induced tumour of BALB/c mice. This cell line was chosen due to the 
stable expression of β2 integrin, CD11b/CD18 (CR3), on its cell surface. CHO K1 and CHO CR3+ cell 
lines are epithelial-like cell lines. In this study CHO CR3+ cell line was used because expresses β2 
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integrin, CD11b/CD18 (CR3), in the cell surface. J774A.1 and J774A.1 CR3- cell lines are 
monocyte/macrophage cell lines obtained from a BALB/c mice with reticulum-like sarcoma. As RAW 
264.7, J774A.1 cell line also presentes a stable expression of β2 integrin, CD11b/CD18 (CR3), on its cell 
surface. Additionally, J774A.1 CR3- cell line, which does not express β2 integrin, was also used in this 
study. 
 
2.11. Cell Culture 
Cells were cultured as exponentially growing subconfluent monolayers and maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, PAA Laboratories GMBH) supplemented with 10% fetal bovine serum 
(FBS) (Invitrogen), 4 mM L-Glutamine (Sigma-Aldrich), Mycokill AB (PAA Laboratories GMBH), and 
penicillin/streptomycin (100 units/ml and 100 µg/ml, respectively) (Invitrogen) in a humidified atmosphere 
consisting of 5% CO2 and 95% air. The culture media used for U87.CD4.CXCR4, CHO CR3+ and 
J774A.1 CR3- cells were also supplemented with 1 µg/ml puromycin and 300 µg/ml Geneticin (G418 
sulphate), 150 µg/ml hygromycin B and 500 µg/ml G418, and 1.5 µg/ml puromycin, respectively. 
 
2.12. Mycoplasma detection assay 
Venor®GeM Mycoplasma Detection Kit was used to discard cell cultures contaminated with 
Mycoplasma. 
 
2.13. Cell cytotoxicity assay 
Cells were seeded in 96-well plates (2.5 × 103 cells/well) and allowed to attach overnight in appropriate 
growth medium. The medium was then replaced with 100 µl OptiMEM serum-free medium (Gibco, 
Invitrogen) in the absence or presence of oligonucleotide conjugates and cells were incubated for 24 h or 
48 h at 37ºC. Cell growth was estimated by measuring the rate of reduction of the tetrazolium dye MTS to 
formazan, as previously described [24, 25]. The absorbance of the medium without cells was subtracted 
from all absorbance values and the control values were considered as 100% of cell viability. Relative cell 
viability of individual samples was calculated by normalizing their absorbance to that of the corresponding 
control sample. 
 
2.14. Cellular binding/uptake studies by flow cytometry 
Cy5- or Alexa 488-labelled ODN was mixed with Transfectin cationic lipid reagent (BIO-RAD), forming 
ODN-lipoplexes in order to compare conjugation and complexation patterns. Lipoplex formation and 
incubation parameters (4 h at 37ºC) were set depending on the maximum transfection yield described for 
Transfectin complexes, following manufacturer’s instructions. Cells were seeded at 1.25 × 105 cells/well in 
24-well plates and incubated overnight in appropriate growth medium. Then cells were incubated in the 
presence of Cy5- or Alexa 488-labelled LOCs, ODN and ODN-lipoplexes at 37°C for 4 h. All these 
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experiments were performed using OptiMEM because the transfection efficiency of several standard 
transfection reagents is reduced in the presence of serum [26-30]. After incubation, cells were completely 
dissociated in 0.5% Trypsin-EDTA (Invitrogen). Trypsin treated cells were washed by centrifugation at 
520 × g for 10 min and then resuspended into ice-cold 1× PBS, followed by a flow cytometry analysis 
(FACSCalibur, Beckton Dickinson) analyzing 10,000 cells per sample. The fluorescence of Alexa 488-
labelled oligonucleotides remaining at the cellular surface was also quenched with 0.2% Trypan Blue 
(final concentration) (Sigma-Aldrich), and subsequently, the fluorescence corresponding to the 
internalized oligonucleotides was measured. Alexa 488 fluorescence was measured using an air-cooled 
488 nm argon-ion laser, collecting emission signals by FL1 detector. In the case of Cy5, an air-cooled 633 
helium-neon ion laser was used and Cy5 emission was collected by FL4 detector. GMFI (Geometric 
Mean Fluorescence Intensity) data of histograms were used for analysis using WinMDI 2.9 and Cell 
Quest (BD Biosciences) softwares. For determining the role of CR3 receptor in LOC uptake, these assays 
were also performed in the presence of fibrinogen, a natural ligand of β2 integrin. 
 
2.15. Cellular localization assays by confocal microscopy 
Cy5- or Alexa 488-labelled ODN was also mixed with Transfectin, forming ODN-lipoplexes. Cells were 
seeded in 8 well-Lab-Tek Chamber slides (5 × 104 cells/well) pre-treated with Poly-L-lysine solution or in 
96 well-BD Falcon™ Tissue Culture Treated Imaging plates (BD Biosciences) (2 × 104 cells/well) in and 
cultured overnight in appropriate growth medium. Cells were then incubated with Cy5- or Alexa 488-
labelled LOCs for 30 min or 4 h at 37ºC in OptiMEM. After incubation, cells were washed three times, 
fixed with 4% (w/v) paraformaldehyde (PFA) for 15 min at room temperature, followed by nucleus staining 
with nuclear marker Hoechst 33258 (Molecular Probes, Invitrogen) for 10 min at room temperature. 
Finally, samples were visualized using Olympus IX 81 inverted fluorescence confocal microscope and 
image acquisition achieved with a digital camera (Axiocam NRc5, Zeiss). The slides were placed on top 
of the microscope for image acquisition with a 20× objective and zoom factor of 2×, using excitation 
wavelengths of 405, 488 and 633 nm for Hoechst 33258, Alexa 488 and Cy5, respectively. The emission 
was recovered between 430-460 nm for Hoechst 33258, 505-525 nm for Alexa 488 and 660-IF nm for 
Cy5. Image treatment was performed using Fluoview v.50 software.  
 
2.16. Cell-surface CR3 receptor staining assay by flow cytometry 
Cell-surface CR3 expression was determined by using anti-CD11b FITC conjugated antibody 
(eBioscience) in CHO K1, CHO CR3+, J774A.1 CR3-, J774A.1 and RAW 264.7 cells. Cells were seeded 
at 1.25 × 105 cells/well in 24-well plates and incubated overnight in appropriate growth medium. Then 
cells were washed twice with 0.1% (w/v) BSA dissolved in 1X PBS, scrapped, centrifuged at 520 × g for 8 
min at 4ºC and resuspended in 200 µl blocking solution [1X PBS containing 0.1% (w/v) BSA and 10% 
(v/v) FBS] for 15 min on ice to block unspecific binding of the antibody. After blocking reaction, cells were 
washed twice with 0.1% (w/v) BSA dissolved in 1X PBS and cell pellets were resuspended with 100 µl 
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anti-CD11b FITC conjugated antibody solution [1X PBS containing 0.1% (w/v) BSA and antibody (1:1000 
dilution)]. Samples were incubated for 1 h on ice. Then, cells were washed twice with 0.1% (w/v) BSA 
dissolved in 1X PBS and fixed with 200 µl 4% (w/v) PFA for 20 min on ice. After fixing treatment, cells 
were washed twice with 0.1% (w/v) BSA dissolved in 1X PBS, followed by flow cytometric analysis. FITC 
fluorescence was measured using an air-cooled 488 nm argon-ion laser, collecting emission signals by 
FL1 detector. 
 
2.17. Statistical analysis 
All measurements were performed at least 3 times, and results are presented as mean ± s.d. Levels of 
significance were determined by a two-tailed Student's t-test, and a confidence level of greater than 95% 
(p<0.05) was used to establish statistical significance. 
 
3. Results and discussion 
3.1. Synthesis of LOCs 
LOCs are a class of bioconjugates that are currently having a great attention from a therapeutic point 
of view, in particular in antisense and RNA interference therapies due to their unique physicochemical 
and biological properties. The introduction of lipid units into oligonucleotides at both 3’- and 5’-termini was 
performed as previously described [20, 21]. For the introduction of lipid units at the 3’-end we selected 
three lipid moieties of different length (12, 14 and 18 C atoms). The lipid-C12NH2 contained a terminal 
amine group. The lipid-C14 was a linear chain totally saturated and the lipid-C18 was a derivative of the 
linoleic acid with 2 unsaturations. As a model DNA sequence we selected the GEM91 sequence (5’-
CTCTCGCACCCATCTCTCTCCTTCT-3’). This oligonucleotide carrying phosphorothioate linkages has 
anti-HIV-1 activity [31]. Modified CPG solid supports (Suppl. Scheme S1, compounds CPG-1, CPG-2 and 
CPG-3) were used for the preparation of the corresponding conjugates (Table 1, compounds 3, 4 and 5) 
modified at 3’-termini.  
We selected two lipids for the 5’-position: A lipid carrying a saturated linear chain of 14 C atoms (lipid-
C14) and a lipid that contains two saturated lineal chains of 14 carbon atoms (lipid-C28). In addition we 
introduced an amino group at the 3’-end for labeling purposes using standard commercial solid supports. 
The introduction of the lipid units was performed using the appropriate lipid phosphoramidites (Suppl. 
Schemes S1 and S2, compounds Ι and ΙΙ) according the literature [32]. The corresponding conjugates 6 
and 7 were obtained in good yields (Fig. 1). For comparative purposes the unmodified oligonucleotide 
sequence carrying the amine modifier at 3’-termini was prepared. All LOC conjugates were successfully 
characterized by HPLC and MALDI-TOF spectrometry (Table 1). The calculated masses were in good 
agreement with the measured values (Table 1).  
 
3.2. Synthesis of fluorescence LOCs modified with Alexa Fluor 488 or Cy5 dyes 
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In order to carry out the membrane binding studies and the cellular uptake experiments, two different 
dyes were introduced into the ODN sequences at either 3’ or 5’-termini. Alexa Fluor 488 (Life 
Technologies) was introduced into the LOC conjugates (Table 1, compounds 6 and 7) along with the 
control oligonucleotide 2 (Table 1), taking advantage of the free amine moiety located at 3’-termini, 
through the post-synthetic approach and according to the literature [33]. The fluorescence oligonucleotide 
conjugates (compounds 10 and 11) were obtained (Fig. 1) and confirmed by MALDI-TOFF mass 
spectrometry (Table 1). The same protocols were applied for the incorporation of Alexa Fluor 488 at 5’-
termini to the rest of modified LOC conjugates (compounds 4 and 5) and unmodified control sequences. 
But, in the case of the lipid conjugates (compounds 12 and 13) it was not possible to separate the 
labelled and unlabelled compounds since according to HPLC analysis, mixtures of starting material and 
labelled oligonucleotides showed in both cases the same retention time.  
Therefore, in order to achieve the fluorescence LOC conjugates modified with lipids at 3’-termini, we 
decided to incorporate Cy5 dye (Glen Research) into the previously synthesized conjugates (compounds 
3-5), through phosphoramidite chemistry approach. After deprotecting and purifying the oligonucleotide 
conjugates by semi-preparative HPLC, we could obtain the corresponding LOC conjugates labelled with 
Cy5 (compounds 15-17) at their 5’-termini. Furthermore, we also obtained the unmodified Cy5-labelled 
oligonucleotide (compound 18) which was used as a control. All conjugates were confirmed by MALDI-
TOFF mass spectrometry (Table 1 and Suppl. Figs. S1-S17).  
 
3.3. Surface activity of LOCs at air-water and lipid-water interfaces 
The Langmuir lipid monolayer technique to mimic half a bilayer may be advantageous because 
properties such as composition, lateral pressure, surface elasticity and surface density are easily 
controlled [34, 35]. First, the surface-active properties of LOCs at an air-water interface were analyzed. All 
LOCs under study caused a dose-dependent increase in surface pressure at the air-water interface, 
except the LOC bearing C12NH2 at the 3’ termini (compound 1), which did not cause any change in 
surface pressure (data not shown). ODN itself was not surface-active either. After a certain time, which 
decreased with increasing LOC concentrations, surface pressure (pi) remained constant (Fig. 2A). This 
constant value was operationally defined as an equilibrium value in this context. In order to compare the 
behaviour of LOCs under the same experimental conditions, pi at 4,000 s was chosen as the equilibrium 
value. As observed in Fig. 2A, the final pi (piF) vs. LOC concentration curves reached a plateau at specific 
LOC concentration, which was used to test LOC insertion into DOPC monolayers at varying initial pi 
values (Fig. 2B). All these data indicate that LOCs surface activity at air-water and lipid-water interfaces 
increased in the following order: ODN-3’-C12NH2 (compound 3) < C14-5’-ODN-3’-NH2 (compound 6) / 
ODN-3’-C14 (compound 4) < NH2-5’-ODN-3’-C18 (compound 9) < C28-5’-ODN-3’-NH2 (compound 7). Most 
importantly, only C28-5’-ODN-3’-NH2 (compound 7) could be inserted into DOPC monolayers at initial 
lateral pressures above those assumed for cell membranes (around 30 mN/m), implying that this 




3.4. Binding of LOCs to lipid bilayer systems 
We investigated the spontaneous incorporation of LOCs into membranes bearing a curvature stress 
and surface charge comparable to those of the plasma membrane surrounding eukaryotic cells by using 
GUVs and SPBs [38-40]. These lipid bilayer systems were composed of DiO- or DiD-labelled 
DOPC/eSM/Chol (2:2:1) in order to analyze the effect of Ld and Lo lipid phase coexistence on LOC 
partitioning. All LOCs showed an apparently similar behaviour in both GUV and SPB systems (Suppl. 
Table S1).  
Cy5-labelled ODN-C12NH2 (compound 15) showed very weak fluorescence in the Ld phase of the 
GUVs that disappeared with prolonged light excitation (Suppl. Fig. S18). Moreover, Cy5-labelled ODN-
C12NH2 (compound 15) did not show any binding to SPB under these conditions (Suppl. Fig. S18). Large 
LOC aggregates were visualized in both GUV and SPB experiments. The reactive primary amine at the 
end of the alkyl chain could be protonated under these experimental conditions (pH 7.4) and bind the 
negatively charged backbone of the oligonucleotide via electrostatic interactions, leading to LOC 
aggregates [41, 42]. Indeed in the complexation strategy the formation of ODN-complexes/aggregates is 
based on the electrostatic interactions between reactive amines of the cationic agents and the negatively 
charged phosphate backbone of the oligonucleotides [43-45].  
ODN-3’-C14 and ODN-3’-C18 compounds behaved differently when conjugated to Cy5 or Alexa 488 
fluorophores. Cy5-labelled C14 and C18 containing LOCs (compounds 16 and 17, respectively) were 
clearly seen in the Ld phase of GUVs and SPBs co-localizing with DiO dye (Suppl. Fig. S19), but when 
conjugated to Alexa 488 they did not show any remarkable interaction or insertion into the lipid bilayer, 
nor did Alexa 488-labelled C14-5’-ODN (compound 10) (Suppl. Fig. S20). This discrepancy may simply be 
due to the presence of the linker in combination with the size and hydrophobicity differences between the 
conjugated fluorophores, which could be incorporated with different efficiencies and/or interfere in the 
stability and/or properties of LOCs. Indeed, Cy5 is more hydrophobic than Alexa 488. Similarly other 
authors have reported that uptake of fluorescein-labelled ODN-conjugates could be altered due to the 
lipophilic nature of this fluorophore [5]. Moreover, since the labelling of these LOCs with Alexa 488 
provided a mixture of labelled and unlabelled products that could not be separated by HPLC a 4% (w/v) 
agarose gel was performed in order to check the state of these LOCs. This assay revealed the poor 
stability of Alexa 488-labelled ODN-3’-C18 (compound 13), which was prone to form aggregates, whereas 
Alexa 488-labelled ODN-3’-C14 (compound 12) behaved similarly to the unlabelled or Cy5-labelled 
compounds (Suppl. Figs. S21 and S22).  
Essentially, it could be reasonably expected that Alexa 488-labelled C28-5’-ODN (compound 11) would 
also spontaneously incorporate into Lo domains since it is long known that dual lipid modification appears 
to facilitate association with lipid rafts [46]. However, this LOC showed a remarkable and rapid 
incorporation into both lipid bilayer phases, being equally distributed between Ld and Lo domains after 
equilibration (Fig. 3). Similar observations have been reported by other authors who used a single 
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cholesterol moiety or two cholesteryl-TEG moieties containing double-stranded DNA structures, which did 
not exclusively partition into the Lo phase [47, 48]. This could be due to the fact that probes designed as 
cholesterol mimics usually do not satisfactorily reproduce the properties of pure cholesterol [47, 48]. 
Alternatively, the presence of two ether bonds in the structure of this LOC could be related to its 
homogeneous distribution in lipid membrane model systems, since ether-linked glycerophospholipids 
appear to be more loosely packed in membranes, thereby increasing their fluidity [49, 50]. In contrast, the 
fact that Alexa 488-labelled C28-5’-ODN (compound 11) compound, that possess two neighbouring alkyl 
chains, could be associated with model membranes is opposite to what it was observed by other authors 
who reported that a lipid-anchored oligonucleotide with two neighbouring alkyl chains may tend to form 
stable supramolecular structures in an aqueous environment, making it difficult to insert into preformed 
membranes [51]. In that case the oligonucleotide was conjugated to a chalcone moiety bearing longer 
alkyl chains (2 × C16) than those of C28-5’-ODN (2 × C14). Our interpretation for this different behaviour 
relies on the higher hydrophobicity of the chalcone moiety with regard to the lipid anchor used in our 
work. Moreover, in SPB experiments reproducible, peculiar Alexa 488-enriched rounded structures were 
observed suggesting that these structures were at least in part formed by this LOC. Importantly, the 
homogeneous distribution of Alexa 488-labelled C28-5’-ODN (compound 11) in liquid domains co-existing 
in bilayers may provide several advantages in cell systems in terms of alternative internalization routes. 
Thus, once this LOC is inserted into the lipid bilayer, it could interact with a number of transmembrane 
proteins involved in distinct uptake pathways, thereby inducing its internalization through different routes. 
 
3.5. Cell cytotoxicity, cellular binding, uptake and localization of LOCs in HeLa cells 
The biological relevance of the above data was also studied by examining the uptake and subcellular 
localization of LOCs in HeLa cells, as this cell line is commonly used to study cell biology of uptake 
mechanisms [52-55]. Mycoplasma free HeLa cultures were used in order to avoid Mycoplasma infection-
induced enhanced oligonucleotide uptake (Suppl. Fig. S23).  
Cell cytotoxicity studies were performed to evaluate the possible toxic effects that these LOCs could 
trigger on HeLa cells. The data showed that these LOCs were neither cytotoxic nor antiproliferative at 5 
µM, except for the LOC bearing a C28 moiety at the 5’-termini of the ODN, which decreased cell viability 
by over 30% and 60% during 24 and 48 h of incubation, respectively (Suppl. Fig. S24). This undesired 
result caused by this LOC is probably related to its high and rapid incorporation into membranes as well 
as to the presence of two ether bonds in this LOC, making it more difficult to degrade [56, 57]. 
The observations of binding/uptake experiments carried out with Cy5-labelled LOCs (Fig. 4A) were 
consistent with those observed in lipid model membrane systems, showing for LOCs bearing C14 and C18 
moieties at the 3’-end of the ODN a remarkable binding/incorporation into both lipid model membranes 
and HeLa cell systems. Instead, Cy5-labelled ODN-3’-C12NH2 (compound 15) showed only a slight 
increase in Cy5 fluorescence, similar to that obtained with Cy5-labelled control-ODN (compound 18) (Fig. 
4A). Similar results were observed by Love and co-workers, who reported that an optimized combination 
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of amine group and tail length is necessary to impart delivery activity since not all tested siRNA 
conjugates carrying a C12-amine part moiety but differing in the amine presentation were successful for 
siRNA silencing, when formulated in combination with other lipids [58]. 
In addition to Cy5-labelled compounds, when HeLa cells were incubated with Alexa 488-labelled LOCs 
(Fig. 4B), they showed a higher cellular uptake as compared to Alexa 488-labelled control-ODN 
(compound 14). In this regard, the following internalization behaviour was observed (from the lowest to 
the highest uptake profile): C14-5’-ODN (compound 10) / ODN-3’-C14 (compound 12) < ODN-3’-C18 
(compound 13) < C28-5’-ODN (compound 11) (Fig. 4B). These results point to a better incorporation when 
longer and dual alkyl chains are conjugated with the ODN (i.e., higher hydrophobicity). However, the latter 
observation is not fully in agreement with the results obtained in GUVs and SPBs with the Alexa 488-
labelled LOCs bearing C14 or C18 moiety at the 3’- or 5’-termini since these LOCs did not show any 
noticeable incorporation into those membrane systems. Presumably, the experimental conditions chosen 
in uptake assays could not be ideal since under these conditions (4 h of incubation) precipitation may 
enhance the association of the LOCs with the cell surface, which could artifactually increase transfection 
rates of the LOCs that apparently do not insert into model membranes [59]. Similarly, these results are in 
agreement with the values obtained by Kubo and co-workers, who reported that palmitic acid (C16)-
conjugated 21-nucleotide siRNA showed very weak fluorescence and insufficient RNAi effect in the 
absence of the transfecting agent Lipofectamine 2000 [60].  
A further aspect that deserves some comment is that Alexa 488-labelled C28-5’-ODN (compound 11) 
showed higher internalization efficiency than that of Alexa 488-labelled ODN-lipoplexes (Fig. 4B). The 
latter result supports the observations reported by Grijalvo and co-workers, where the siRNA carrying the 
C28 moiety at the 5’-end of the passenger strand showed the best inhibitory effects in the absence of the 
transfecting agent Oligofectamine. Even more, this compound was the less active siRNA conjugate when 
combined with the transfecting agent [21]. Also, Lindner and co-workers convincingly demonstrated that 
myristoyl chains seem to play an important role in cationic liposome-mediated ODN delivery, as in a 
functional assay with ODN dimyristoyl analogs were the best cationic lipids for ODN transfection even in 
the absence of helper lipids [57]. 
Subcellular localization assays revealed that all LOCs, as well as control-ODNs, were visualized in the 
nucleus of HeLa cells, indicating that these lipid moieties conjugated to ODN do not interfere with the 
ODN destination (Fig. 5). Moreover, when the experiments were achieved either in the absence or 
presence of Transfectin same nuclear localization was observed, suggesting that conjugation and 
complexation approaches are equaly efficient (Fig. 5A and 5B). 
Regarding cellular uptake and subcellular localization of LOCs, both Cy5- and Alexa 488-labelled 
LOCs were detected in the nucleus of HeLa cells as control ODNs (Fig. 5C and 5D).  
In particular, the LOC containing a C28 moiety showed very high fluorescence localized in the nucleus 
of HeLa cells, with small intense fluorescent spots within it (Fig. 5D), suggesting that the concentration 
used (500 nM) in this assay could be saturating due to its high and rapid incorporation into cells. 
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Strikingly, when a lower concentration of this LOC was tested (50 nM), this compound was still capable of 
reaching the nucleus even after 30 min incubation, exhibiting a redistribution from the nucleus to the 
cytoplasmic membrane-bound compartments and membrane-like regions at longer periods of time (4 h) 
(Suppl. Fig. S25) [61]. The latter observation underscores the fact that the C28 lipid modification seems to 
be a promising moiety for small nucleic acid-based delivery since it does not interfere with the ODN 
destination or disrupt RNAi machinery when conjugated to siRNA [21]. 
 
3.6. Cell cytotoxicity, cellular binding, uptake and localization of C28-5’-ODN in different cell lines 
In order to demonstrate whether the results obtained by C28-5’-ODN in HeLa cells were more generally 
applicable, eight more cell lines were examined (PANC-1, C2C12, CHO K1, CHO CR3+, J774A.1 CR3-, 
J774A.1, RAW 267). This LOC did not show any cytotoxic effect in all cell lines tested during 24 h of 
incubation (Fig. 6A). Subsequently, cellular uptake in these cell lines was analyzed. As expected, this 
LOC was better internalized in all cell lines tested compared to control-ODN (Fig. 6B). In particular, cells 
expressing CR3 receptor (i.e., CHO CR3+, J774A.1 and RAW 264.7 cells) showed an enhanced LOC 
uptake even at 100 nM LOC, compared to cells lacking this receptor (i.e., CHO K1 and J774A.1 CR3- 
cells). Indeed, J774A.1 and RAW 264.7 cells cell lines showed the highest uptake behaviour, in 
agreement with previous reports that suggested an enhanced ODN internalization mediated by β2 
integrins [62]. 
Despite the universality in membrane traffic, each cell type shows major unique features which 
obviously may influence intracellular delivery and traffic of the compound to be internalized [63]. Thus, it 
can be assumed that a particular cell type may select a specific uptake pathway for the internalization of a 
delivery system leading to an uptake efficiency, which may largely differ from those achieved by other cell 
types selecting different internalization routes. Related to this assumption, different results have been 
obtained in the cellular uptake (Fig. 6B) and subcellular localization (Fig. 7) where C28-5’-ODN can be 
localized mostly in the nucleus of several but not all the cell lines tested under these experimental 
conditions. HeLa, PANC-1 and C2C12 cells first showed a nuclear LOC localization (30 min) that was 
further redistributed into the cell cytoplasm after longer time periods (4 h). Likewise, the transport of 
ODNs first to and then out of the nucleus has already been reported [61]. These observations are also in 
agreement with the results achieved by other authors who reported that the efficiency of cellular 
accumulation of lipophilic siRNAs was dependent upon the type of cell line tested [29]. 
By contrast, weak fluorescence was observed in the nucleus of U87.CD4.CXCR4, CHO CR3+, 
J774A.1 and RAW264.7 cell lines, being more noticeable at the cell cytoplasm both at short and long time 
periods. Finally, CHO K1 and J774A.1 CR3- cell lines showed very weak fluorescence at either 30 min or 
4 h incubation times, suggesting an inefficient LOC uptake (Fig. 7). 
 
3.7. Role of CR3 receptor in the enhancement of C28-5’-ODN internalization 
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Related to the results obtained by CR3-presenting cell lines, previous investigations established an 
important role of these
 
integrins in the enhancement of ODN internalization, thereby promoting a receptor-
mediated endocytosis [62]. Thus, we examined whether this enhanced LOC internalization was mediated 
by this receptor. First cell surface CR3 expression was analyzed by flow cytometry. It was confirmed that 
CHO CR3+, J774A.1 and RAW 264.7 expressed CR3 integrin (Suppl. Fig S26). In this experiment CHO 
K1 and J774A.1 CR3- cell lines were used as negative controls.  
To perform a deeper analysis of the involvement of CR3 integrin in the LOC uptake, soluble fibrinogen, 
a natural ligand for this integrin, was selected to compete with the LOC for the binding sites of this 
receptor, thereby blocking LOC internalization, as previously reported by other authors [62, 64-66]. In this 
experiment, again CHO K1 and J774A.1 CR3- cell lines were used as negative controls for CR3-
mediated LOC internalization, assuming that in these cell lines LOC uptake did not vary in the presence 
of soluble fibrinogen as observed in Fig. 8A. On the contrary, in the presence of soluble fibrinogen the 
cellular uptake of this LOC was significantly blocked in CR3 presenting cells (i.e., CHO CR3+, J774A.1 
and RAW 264.7 cells). In fact, cellular uptake is inhibited at least up to 30% in the presence of 500 nM 
soluble fibrinogen. These results suggest the direct involvement of this receptor in LOC internalization 
(Fig. 8).  
In conclusion, LOCs presenting longer or double-tailed lipid modifications (i.e., with higher 
hydrophobicity) showed the best incorporation behaviour into both membrane lipid model and cell 
systems. Interestingly, the dual saturated lipid neighbouring moiety (C28) at the 5’-termini of the ODN, 
which showed potencial silencing activity when conjugated to siRNA in the absence of tranfection 
reagents, turn out to be the most powerful lipophilic anchor tested, even better than the internalization 
provided by the commercial lipoplexes tested in this study, being capable of inserting into both Ld and Lo 
domains. Moreover, C28 lipid moiety provides better cellular incorporation of ODN without causing 
cytotoxicity in cells or altering the binding properties of the ODN itself, thereby enabling binding to 
different molecules, such as receptors present on the cell-surface, intracellular proteins involved in the 
intracellular ODN transport and target mRNA molecules. All these features make C28 lipid modification a 

















Fig. 1. Left: Schematic representation of lipid modifications introduced into the oligonucleotides. A) 
Selected lipids (R1) were bound to the 3’-end. B) Selected lipids (R2) were bound to the 5’-termini. Right: 
Schematic representation of the lipid oligonucleotide conjugates labelled with A) Alexa Fluor 488 and B) 







Fig. 2. Surface activity of LOCs in free-lipid and DOPC monolayes. A) Changes in surface pressure at the 
air-water interface induced by LOCs [compounds 4 (ODN-3’-C14), 6 (C14-5’-ODN-3’-NH2), 7 (C28-5’-ODN-
3’-NH2), and 9 (NH2-5’-ODN-3’-C18)]. Final pi values obtained from LOCs at 4,000 s incubation with 
constant stirring. B) Changes in surface pressure of DOPC monolayers oriented at the air-water interface 
as a result of LOC insertion (compounds 4, 6, 7 and 9) at varying initial pressures. The plateau values of 
surface pressure increases (∆pi) after LOC insertion are plotted as a function of the initial pi (pii). Average 

















Fig. 3. Imaging of Alexa 488-labelled C28-5’-ODN binding to GUVs and SPBs. Confocal microscopy 
images of DiD-labelled DOPC/eSM/Chol (2:2:1) GUVs [equatorial sections (upper panels); 3D 
reconstruction (bottom panels)] incubated with 50 nM of Alexa 488-labelled C28-5’-ODN (compound 11) 
for 1 h (A) and 2 h (B). Scale bars represent 5 µm. C) Confocal microscopy images of DiD-labelled 
DOPC/eSM/Chol (2:2:1) SPBs incubated with Alexa 488-labelled C28-5’-ODN (compound 11). First, 25 
nM Alexa 488-labelled C28-5’-ODN (compound 11) were added to the SPBs and incubated for 15 min. 
Then, additional 25 nM Alexa 488-labelled C28-5’-ODN (compound 11) were added to the sample and 
incubated for another 15 min. White squares represent the zoomed regions, corresponding to the images 
below. LOC (green) and lipid (red) staining are shown in the left and centre columns, respectively. The 








Fig. 4. Cellular binding/uptake of LOCs in HeLa cells. Cells were incubated with 500 nM Cy5- or Alexa 
488-labelled control-ODNs, ODN-lipoplexes and LOCs for 4 h at 37ºC in OptiMEM. After incubation, cells 
were washed three times, resuspended in ice-cold PBS, and analyzed by flow cytometry. GMFI 
corresponds to Geometric Mean of Fluorescence Intensity. Control stands for untreated cells, 
representing cell basal fluorescence intensity; (ODN + T) corresponds to lipoplexes formed by the 
complexation of Cy5-5’-ODN (compound 18) or ODN-3’-Alexa 488 (compound 14) with Transfectin. 
Results are expressed as GMFI ± SEM of 3 independent experiments performed in duplicate (*p<0.05; 
**p<0.01). A) Total cellular fluorescence observed after incubation with Cy5-labelled ODN (compound 18) 
and Cy5-labelled LOCs: ODN-3’-C12-NH2 (compound 15), ODN-3’-C14 (compound 16) and ODN-3’-C18 
(compound 17). B) Total cellular fluorescence (black columns) and internalized fluorescence (gray 
columns) of Alexa 488-labelled ODN (compound 14) and Alexa 488-labelled LOCs: C14-5’-ODN 
(compound 10), ODN-3’-C14 (compound 12), ODN-3’-C18 (compound 13) and C28-5’-ODN (compound 11). 




Fig. 5. Cellular uptake and subcellular localization of Cy5- and Alexa 488-labelled ODN and LOCs in 
HeLa cells. A) Cells were incubated with 500 nM Cy5-5’-ODN (compound 18) (upper panels) or ODN-3’-
Alexa 488 (compound 14) (bottom panels) for 4h at 37ºC in OptiMEM. B) Cells were incubated with 500 
nM ODN-lipoplexes for 4 h at 37ºC in OptiMEM. (ODN + T) correspond to lipoplexes formed by the 
complexation of Cy5-5’-ODN (compound 18) (upper panels) or ODN-3’-Alexa 488 (compound 14) (bottom 
panels) with Transfectin, respectively. C and D) Cells were incubated with 500 nM Cy5-labelled LOCs: 
ODN-3’-C12-NH2 (compound 15), ODN-3’-C14 (compound 16), ODN-3’-C18 (compound 17) (C) and with 
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Alexa 488-labelled LOCs: C14-5’-ODN (compound 10), ODN-3’-C14 (compound 12), ODN-3’-C18 
(compound 13), C28-5’-ODN (compound 11) (D) for 4 h at 37ºC in OptiMEM. After incubation, cells were 
washed three times, fixed with 4% (w/v) PFA and treated with Hoechst 33258 for nucleus staining. 
Nucleus (blue) and LOC (green) staining are shown in the left-hand and centre columns, respectively. 
























Fig. 6. Cell cytotoxicity and cellular uptake assays of C28-5’-ODN in different cell lines. A) Cell cytotoxicity 
assay. Cells were seeded (5 × 103 cells/well) in 96 well plates and incubated overnight in appropriate 
growth medium. Then, cells were incubated in 100 µl OptiMEM in the absence or presence of 1 µM 
control-ODN (ODN) (compound 2) or C28-5’-ODN (LOC) (compound 7) for 24 h at 37ºC. Untreated cells 
were used as negative control (Control). Data were normalized to the control value (untreated cells at 0 h 
of incubation) and are expressed as the mean ± SEM of 3 independent experiments performed in 
triplicate (*p<0.05; **p<0.01; *** p<0.001). B) Cellular uptake assay. Cells were seeded (1.25 × 105 
cells/well) in 24 well plates and cultured overnight in appropriate growth medium. Then, cells were 
incubated with 500 nM ODN-3’-Alexa 488 (ODN) (compound 14) or 100 and 500 nM Alexa 488-labelled 
C28-5’-ODN (LOC) (compound 11) for 4 h at 37ºC in OptiMEM. After incubation, cells were washed three 
times, resuspended in ice-cold PBS, and analyzed by flow cytometry. Control stands for untreated cells, 
representing cell basal fluorescence intensity. GMFI corresponds to Geometric Mean of Fluorescence 
Intensity. Results are expressed as GMFI ± SEM of 3 independent experiments performed in duplicate 





Fig. 7. Cellular uptake and subcellular localization of Alexa 488-labelled C28-5’-ODN in different cell lines. 
Cells were incubated with 100 nM Alexa Alexa 488-labelled C28-5’-ODN (compound 11) in for 30 min (left 
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panels) or 4 h (right panels) at 37ºC in OptiMEM. After incubation, cells were washed three times, fixed 
with 4% (w/v) PFA and treated with Hoechst for nucleus staining. Nucleus (blue) and C28 moiety bearing 
LOC (green) staining are shown in the left and centre columns, respectively. The right column displays 
























Fig. 8. Effects of the soluble fibrinogen on cellular uptake of Alexa 488-labelled C28-5’-ODN in CHO K1, 
CHO CR3+, J774A.1 CR3-, J774A.1 and RAW264.7 cells. Cells were seeded (1.25 × 105 cells/well) in 24 
well plates and cultured overnight in appropriate growth medium. Then, cells were pretreated in the 
presence of 100 nM or 500 nM soluble fibrinogen (Fib) for 30 min at 37ºC in OptiMEM. Next, cells were 
incubated with 100 nM Alexa 488-labelled C28(5’)-GEM91 for 30 min at 37ºC. After incubation, cells were 
washed three times, resuspended in ice-cold PBS, and analyzed by flow cytometry. A) LOC 
internalization in the presence of fibrinogen. Control stands for untreated cells, representing cell basal 
fluorescence intensity. GMFI corresponds to Geometric Mean of Fluorescence Intensity. Results are 
expressed as GMFI ± SEM of 4 independent experiments performed in duplicate (*p<0.05; **p<0.01; 
***p<0.001). B) LOC internalization percentage in the presence of fibrinogen. Cellular uptake achieved in 
the absence of soluble fibrinogen was considered as the maximum internalization (100%). Results are 
expressed as percentage of cellular uptake ± SEM of 4 independent experiments performed in duplicate 







Table 1  






1, 5′-CTCTCGCACCCATCTCTCTCCTTCT-3′ 7387 7384 
2, 5′-CTCTCGCACCCATCTCTCTCCTTCT-3′-NH2 7601 7604 
3, 5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-[C12NH2]  7725 7722 
4, 5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-[C14] 7738 7734 
5, 5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-[C18] 7790 7795 
6, [C14]-5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-NH2 7877 7882 
7, [C28]-5′-CTCTCGCACCCATCTCTCTCCTTCT-3′-NH2 8147 8149 
8, NH2-5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-[C14] 7917 79861 
9, NH2-5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-[C18] 7969 7962 
10, [C14]-5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-NHCO-Alexa 488 8359 8353 
11, [C28]-5′-CTCTCGCACCCATCTCTCTCCTTCT-3′-NHCO-Alexa 488 8629 8631 
12, Alexa 488-CONH-5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-[C14] 8435 84971,4 
13, Alexa 488-CONH-5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-[C18] 8472 84774 
14, 5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-NHCO-Alexa 488 8118 81173 
15, Cy5-5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-[C12 NH2] 8273 82932 
16, Cy5-5’-CTCTCGCACCCATCTCTCTCCTTCT-3’-[C14] 8260 8267 
17, Cy5-5′-CTCTCGCACCCATCTCTCTCCTTCT-3′-[C18] 8330 8328 
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